By Shelly Kumar
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.
“The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers
Q BioMed Inc. (OTCQB:QBIO), is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors provides the necessary capital to meet near term milestones and catalysts in its most advanced product portfolio assets, including the commercialization of Strontium Chloride 89, multiple IND
Premier Biomedical shared the publication of an update letter to shareholders from the company’s CEO.
Premier Biomedical announced it has terminated joint venture Premier Biomedical Pain Management Solutions.
By Shelly Kumar
Q BioMed Inc. (OTCQB:QBIO) will be featured on CEO Clips airing on Bloomberg Television July 10 through 14th. CEO Clips, profiles some of the most innovative publicly traded companies in North America and will feature a :15 to :30 sec clip about Q BioMed on Bloomberg Television beginning today and
SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Q BioMed Inc. (OTCQB:QBIO).
Q BioMed Inc. (OTCQB: QBIO) is a biomedical acceleration and development company focused on identifying, acquiring and licensing attractive biomedical assets from small
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.
Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. A long-time veteran of Amersham Health and
Friday Night Inc. (the “Company”) (CSE:TGIF) (FRANKFURT:1QF) has entered into a production and distribution licensing agreement (the “Licensing Agreement”) with Gilla Enterprises Inc. (“Gilla”), a wholly-owned subsidiary of Gilla Inc. (OTCQB:GLLA), to introduce and launch Gilla’s new portfolio of cannabis concentrate products in the State of Nevada. The Licensing Agreement
Q BioMed Inc. (OTCQB:QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat
Friday Night Inc, formerly QuikFlo Health Inc. (the “Company”) (CSE:TGIF) (FRANKFURT:1QF) announces that in conjunction with the closing of its previously announced acquisition of interests in two cannabis based businesses located in Las Vegas, Nevada, it has changed its name to Friday Night Inc. and consolidated its shares on a
By Jocelyn Aspa
PyroGenesis Canada (TSXV:PYR) has announced that it has created a new division under the name of “PyroGenesis Additive,” dedicated primarily to PyroGenesis’ additive manufacturing line.
As quoted in the press release:
PyroGenesis is the inventor of Plasma Atomization, using this process to produce very small, uniform, fully dense and spherical metal powders
Q BioMed Inc. (OTCQB:QBIO) , a biotechnology acceleration company, announced today that it will be a featured presenter at the 6th Annual Marcum MicroCap Conference on Thursday, June 15, 2017 in New York City at the Grand Hyatt Hotel.
The Company’s presentation by Denis Corin, Q BioMed Inc. CEO, is scheduled